Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market Growth 2026-2032
The global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market size is predicted to grow from US$ 9242 million in 2025 to US$ 26445 million in 2032; it is expected to grow at a CAGR of 16.4% from 2026 to 2032.
PARP inhibitors are a class of targeted anticancer agents that inhibit poly (ADP-ribose) polymerase enzymes involved in single-strand DNA repair. By blocking PARP activity, they induce accumulation of DNA damage and exploit homologous recombination deficiency (HRD), particularly in BRCA1/2-mutated tumors, leading to synthetic lethality and selective tumor cell death. They represent a key modality in precision oncology.
Nominal capacity is constrained by innovative drug manufacturing systems, translating into less than 100 tons of combined API and formulation capacity, reflecting a high-value, low-volume profile. Mechanistically, these agents inhibit PARP-mediated single-strand DNA repair and induce synthetic lethality in BRCA- or HRD-deficient tumors, forming an oligopolistic structure led by Olaparib under AstraZeneca, with Niraparib and Talazoparib as key complements and Chinese agents Fluzoparib and Pamiparib providing price-tier differentiation. The classification framework includes six commercial molecules and biomarker-based segmentation into BRCA, HRD, and all-comer populations; on the application side, combination regimens have become the dominant growth driver, with PARP+AR and PARP+IO enabling indication expansion, where ovarian cancer remains the core base at around 50% while prostate cancer represents the fastest-growing segment with share exceeding 30%. Pricing shows strong regional divergence, with annual therapy costs of USD 120k?180k per patient in the US and Europe versus USD 20k?50k in China, implying a global blended price of USD 100k?120k per patient and gross margins typically at 85?92%. Upstream consists of small-molecule APIs and advanced CDMO systems, while downstream includes oncology hospitals and BRCA/HRD companion diagnostics, resulting in a highly concentrated global structure with the top three players accounting for over 80% alongside rapid penetration of domestic Chinese alternatives. Overall, the industry has transitioned from a target-driven phase to one driven by indication expansion and combination regimens, with growth primarily fueled by prostate cancer expansion and combination adoption, while key uncertainty lies in variable PARP+IO efficacy and potential substitution by next-generation DDR targets.
LP Information, Inc. (LPI) ' newest research report, the ?Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Industry Forecast? looks at past sales and reviews total world Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) sales in 2025, providing a comprehensive analysis by region and market sector of projected Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) sales for 2026 through 2032. With Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) industry.
This Insight Report provides a comprehensive analysis of the global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors).
This report presents a comprehensive overview, market shares, and growth opportunities of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market?
What factors are driving Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market opportunities vary by end market size?
How does Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) break out by Type, by Application?
PARP inhibitors are a class of targeted anticancer agents that inhibit poly (ADP-ribose) polymerase enzymes involved in single-strand DNA repair. By blocking PARP activity, they induce accumulation of DNA damage and exploit homologous recombination deficiency (HRD), particularly in BRCA1/2-mutated tumors, leading to synthetic lethality and selective tumor cell death. They represent a key modality in precision oncology.
Nominal capacity is constrained by innovative drug manufacturing systems, translating into less than 100 tons of combined API and formulation capacity, reflecting a high-value, low-volume profile. Mechanistically, these agents inhibit PARP-mediated single-strand DNA repair and induce synthetic lethality in BRCA- or HRD-deficient tumors, forming an oligopolistic structure led by Olaparib under AstraZeneca, with Niraparib and Talazoparib as key complements and Chinese agents Fluzoparib and Pamiparib providing price-tier differentiation. The classification framework includes six commercial molecules and biomarker-based segmentation into BRCA, HRD, and all-comer populations; on the application side, combination regimens have become the dominant growth driver, with PARP+AR and PARP+IO enabling indication expansion, where ovarian cancer remains the core base at around 50% while prostate cancer represents the fastest-growing segment with share exceeding 30%. Pricing shows strong regional divergence, with annual therapy costs of USD 120k?180k per patient in the US and Europe versus USD 20k?50k in China, implying a global blended price of USD 100k?120k per patient and gross margins typically at 85?92%. Upstream consists of small-molecule APIs and advanced CDMO systems, while downstream includes oncology hospitals and BRCA/HRD companion diagnostics, resulting in a highly concentrated global structure with the top three players accounting for over 80% alongside rapid penetration of domestic Chinese alternatives. Overall, the industry has transitioned from a target-driven phase to one driven by indication expansion and combination regimens, with growth primarily fueled by prostate cancer expansion and combination adoption, while key uncertainty lies in variable PARP+IO efficacy and potential substitution by next-generation DDR targets.
LP Information, Inc. (LPI) ' newest research report, the ?Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Industry Forecast? looks at past sales and reviews total world Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) sales in 2025, providing a comprehensive analysis by region and market sector of projected Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) sales for 2026 through 2032. With Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) industry.
This Insight Report provides a comprehensive analysis of the global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors).
This report presents a comprehensive overview, market shares, and growth opportunities of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Olaparib
- Niraparib
- Talazoparib
- Rucaparib
- Fluzoparib
- Pamiparib
- BRCA-mutated
- HRD-positive Broader Population
- All-comers
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
- Other HRD tumors
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- GlaxoSmithKline?GSK?
- Pfizer
- Bristol Myers Squibb?BMS?
- Jiangsu Hengrui Pharmaceuticals
- BeiGene
- Johnson & Johnson
- Merck & Co.
What is the 10-year outlook for the global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market?
What factors are driving Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) market opportunities vary by end market size?
How does Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Country/Region, 2021, 2025 & 2032
2.2 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Segment by Type
2.2.1 Olaparib
2.2.2 Niraparib
2.2.3 Talazoparib
2.2.4 Rucaparib
2.2.5 Fluzoparib
2.2.6 Pamiparib
2.2.7 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type
2.2.7.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
2.2.7.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Type (2021-2026)
2.3 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Segment by Patient
2.3.1 BRCA-mutated
2.3.2 HRD-positive Broader Population
2.3.3 All-comers
2.3.4 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Patient
2.3.4.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Patient (2021-2026)
2.3.4.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue and Market Share by Patient (2021-2026)
2.3.4.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Patient (2021-2026)
2.4 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Segment by Application
2.4.1 Ovarian Cancer
2.4.2 Breast Cancer
2.4.3 Prostate Cancer
2.4.4 Pancreatic Cancer
2.4.5 Other HRD tumors
2.4.6 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application
2.4.6.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Market Share by Application (2021-2026)
2.4.6.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue and Market Share by Application (2021-2026)
2.4.6.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Breakdown Data by Company
3.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales by Company (2021-2026)
3.1.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Company (2021-2026)
3.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue by Company (2021-2026)
3.2.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Company (2021-2026)
3.2.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Company (2021-2026)
3.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Company
3.4 Key Manufacturers Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Location Distribution
3.4.2 Players Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR POLY ADP-RIBOSE POLYMERASE INHIBITORS(PARP INHIBITORS) BY GEOGRAPHIC REGION
4.1 World Historic Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market Size by Geographic Region (2021-2026)
4.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market Size by Country/Region (2021-2026)
4.2.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
4.4 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
4.5 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
4.6 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
5 AMERICAS
5.1 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country
5.1.1 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026)
5.1.2 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026)
5.2 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
5.3 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Region
6.1.1 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Region (2021-2026)
6.1.2 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Region (2021-2026)
6.2 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
6.3 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Country
7.1.1 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026)
7.1.2 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026)
7.2 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
7.3 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Country
8.1.1 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026)
8.2 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
8.3 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
10.3 Manufacturing Process Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
10.4 Industry Chain Structure of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Distributors
11.3 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Customer
12 WORLD FORECAST REVIEW FOR POLY ADP-RIBOSE POLYMERASE INHIBITORS(PARP INHIBITORS) BY GEOGRAPHIC REGION
12.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market Size Forecast by Region
12.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Forecast by Region (2027-2032)
12.1.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Forecast by Type (2027-2032)
12.7 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.1.3 AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 GlaxoSmithKline?GSK?
13.2.1 GlaxoSmithKline?GSK? Company Information
13.2.2 GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.2.3 GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GlaxoSmithKline?GSK? Main Business Overview
13.2.5 GlaxoSmithKline?GSK? Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.3.3 Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Bristol Myers Squibb?BMS?
13.4.1 Bristol Myers Squibb?BMS? Company Information
13.4.2 Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.4.3 Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bristol Myers Squibb?BMS? Main Business Overview
13.4.5 Bristol Myers Squibb?BMS? Latest Developments
13.5 Jiangsu Hengrui Pharmaceuticals
13.5.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.5.2 Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.5.3 Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.5.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.6 BeiGene
13.6.1 BeiGene Company Information
13.6.2 BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.6.3 BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 BeiGene Main Business Overview
13.6.5 BeiGene Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.7.3 Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Merck & Co.
13.8.1 Merck & Co. Company Information
13.8.2 Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.8.3 Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Merck & Co. Main Business Overview
13.8.5 Merck & Co. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Country/Region, 2021, 2025 & 2032
2.2 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Segment by Type
2.2.1 Olaparib
2.2.2 Niraparib
2.2.3 Talazoparib
2.2.4 Rucaparib
2.2.5 Fluzoparib
2.2.6 Pamiparib
2.2.7 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type
2.2.7.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
2.2.7.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Type (2021-2026)
2.3 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Segment by Patient
2.3.1 BRCA-mutated
2.3.2 HRD-positive Broader Population
2.3.3 All-comers
2.3.4 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Patient
2.3.4.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Patient (2021-2026)
2.3.4.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue and Market Share by Patient (2021-2026)
2.3.4.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Patient (2021-2026)
2.4 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Segment by Application
2.4.1 Ovarian Cancer
2.4.2 Breast Cancer
2.4.3 Prostate Cancer
2.4.4 Pancreatic Cancer
2.4.5 Other HRD tumors
2.4.6 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application
2.4.6.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Market Share by Application (2021-2026)
2.4.6.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue and Market Share by Application (2021-2026)
2.4.6.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Breakdown Data by Company
3.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales by Company (2021-2026)
3.1.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Company (2021-2026)
3.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue by Company (2021-2026)
3.2.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Company (2021-2026)
3.2.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Company (2021-2026)
3.3 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Company
3.4 Key Manufacturers Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Location Distribution
3.4.2 Players Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR POLY ADP-RIBOSE POLYMERASE INHIBITORS(PARP INHIBITORS) BY GEOGRAPHIC REGION
4.1 World Historic Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market Size by Geographic Region (2021-2026)
4.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market Size by Country/Region (2021-2026)
4.2.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
4.4 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
4.5 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
4.6 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth
5 AMERICAS
5.1 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country
5.1.1 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026)
5.1.2 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026)
5.2 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
5.3 Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Region
6.1.1 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Region (2021-2026)
6.1.2 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Region (2021-2026)
6.2 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
6.3 APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Country
7.1.1 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026)
7.1.2 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026)
7.2 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
7.3 Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) by Country
8.1.1 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026)
8.2 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026)
8.3 Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
10.3 Manufacturing Process Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
10.4 Industry Chain Structure of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Distributors
11.3 Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Customer
12 WORLD FORECAST REVIEW FOR POLY ADP-RIBOSE POLYMERASE INHIBITORS(PARP INHIBITORS) BY GEOGRAPHIC REGION
12.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market Size Forecast by Region
12.1.1 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Forecast by Region (2027-2032)
12.1.2 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Forecast by Type (2027-2032)
12.7 Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.1.3 AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 GlaxoSmithKline?GSK?
13.2.1 GlaxoSmithKline?GSK? Company Information
13.2.2 GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.2.3 GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GlaxoSmithKline?GSK? Main Business Overview
13.2.5 GlaxoSmithKline?GSK? Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.3.3 Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Bristol Myers Squibb?BMS?
13.4.1 Bristol Myers Squibb?BMS? Company Information
13.4.2 Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.4.3 Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Bristol Myers Squibb?BMS? Main Business Overview
13.4.5 Bristol Myers Squibb?BMS? Latest Developments
13.5 Jiangsu Hengrui Pharmaceuticals
13.5.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.5.2 Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.5.3 Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.5.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.6 BeiGene
13.6.1 BeiGene Company Information
13.6.2 BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.6.3 BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 BeiGene Main Business Overview
13.6.5 BeiGene Latest Developments
13.7 Johnson & Johnson
13.7.1 Johnson & Johnson Company Information
13.7.2 Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.7.3 Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Johnson & Johnson Main Business Overview
13.7.5 Johnson & Johnson Latest Developments
13.8 Merck & Co.
13.8.1 Merck & Co. Company Information
13.8.2 Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
13.8.3 Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Merck & Co. Main Business Overview
13.8.5 Merck & Co. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Olaparib
Table 4. Major Players of Niraparib
Table 5. Major Players of Talazoparib
Table 6. Major Players of Rucaparib
Table 7. Major Players of Fluzoparib
Table 8. Major Players of Pamiparib
Table 9. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 10. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Table 11. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Type (2021-2026) & ($ million)
Table 12. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Type (2021-2026)
Table 13. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Type (2021-2026) & (US$/Ton)
Table 14. Major Players of BRCA-mutated
Table 15. Major Players of HRD-positive Broader Population
Table 16. Major Players of All-comers
Table 17. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Patient (2021-2026) & (Tons)
Table 18. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Patient (2021-2026)
Table 19. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Patient (2021-2026) & ($ million)
Table 20. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Patient (2021-2026)
Table 21. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Patient (2021-2026) & (US$/Ton)
Table 22. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale by Application (2021-2026) & (Tons)
Table 23. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Market Share by Application (2021-2026)
Table 24. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Application (2021-2026) & ($ million)
Table 25. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Application (2021-2026)
Table 26. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Application (2021-2026) & (US$/Ton)
Table 27. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Company (2021-2026) & (Tons)
Table 28. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Company (2021-2026)
Table 29. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Company (2021-2026) & ($ millions)
Table 30. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Company (2021-2026)
Table 31. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Company (2021-2026) & (US$/Ton)
Table 32. Key Manufacturers Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Producing Area Distribution and Sales Area
Table 33. Players Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Products Offered
Table 34. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 35. New Products and Potential Entrants
Table 36. Market M&A Activity & Strategy
Table 37. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Geographic Region (2021-2026) & (Tons)
Table 38. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share Geographic Region (2021-2026)
Table 39. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 40. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Geographic Region (2021-2026)
Table 41. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country/Region (2021-2026) & (Tons)
Table 42. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country/Region (2021-2026)
Table 43. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country/Region (2021-2026) & ($ millions)
Table 44. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country/Region (2021-2026)
Table 45. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026) & (Tons)
Table 46. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country (2021-2026)
Table 47. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026) & ($ millions)
Table 48. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 49. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 50. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Region (2021-2026) & (Tons)
Table 51. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Region (2021-2026)
Table 52. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Region (2021-2026) & ($ millions)
Table 53. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 54. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 55. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026) & (Tons)
Table 56. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026) & ($ millions)
Table 57. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 58. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 59. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026) & (Tons)
Table 60. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country (2021-2026)
Table 61. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 62. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 63. Key Market Drivers & Growth Opportunities of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Table 64. Key Market Challenges & Risks of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Table 65. Key Industry Trends of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Table 66. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Raw Material
Table 67. Key Suppliers of Raw Materials
Table 68. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Distributors List
Table 69. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Customer List
Table 70. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Region (2027-2032) & (Tons)
Table 71. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 72. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Country (2027-2032) & (Tons)
Table 73. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 74. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Region (2027-2032) & (Tons)
Table 75. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Country (2027-2032) & (Tons)
Table 77. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Country (2027-2032) & (Tons)
Table 79. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Type (2027-2032) & (Tons)
Table 81. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 82. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Application (2027-2032) & (Tons)
Table 83. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 84. AstraZeneca Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 85. AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 86. AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 87. AstraZeneca Main Business
Table 88. AstraZeneca Latest Developments
Table 89. GlaxoSmithKline?GSK? Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 90. GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 91. GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 92. GlaxoSmithKline?GSK? Main Business
Table 93. GlaxoSmithKline?GSK? Latest Developments
Table 94. Pfizer Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 96. Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. Bristol Myers Squibb?BMS? Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 100. Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 101. Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 102. Bristol Myers Squibb?BMS? Main Business
Table 103. Bristol Myers Squibb?BMS? Latest Developments
Table 104. Jiangsu Hengrui Pharmaceuticals Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 105. Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 106. Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 107. Jiangsu Hengrui Pharmaceuticals Main Business
Table 108. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 109. BeiGene Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 110. BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 111. BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 112. BeiGene Main Business
Table 113. BeiGene Latest Developments
Table 114. Johnson & Johnson Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 115. Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 116. Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 117. Johnson & Johnson Main Business
Table 118. Johnson & Johnson Latest Developments
Table 119. Merck & Co. Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 120. Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 121. Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 122. Merck & Co. Main Business
Table 123. Merck & Co. Latest Developments
Table 1. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Olaparib
Table 4. Major Players of Niraparib
Table 5. Major Players of Talazoparib
Table 6. Major Players of Rucaparib
Table 7. Major Players of Fluzoparib
Table 8. Major Players of Pamiparib
Table 9. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 10. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Table 11. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Type (2021-2026) & ($ million)
Table 12. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Type (2021-2026)
Table 13. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Type (2021-2026) & (US$/Ton)
Table 14. Major Players of BRCA-mutated
Table 15. Major Players of HRD-positive Broader Population
Table 16. Major Players of All-comers
Table 17. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Patient (2021-2026) & (Tons)
Table 18. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Patient (2021-2026)
Table 19. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Patient (2021-2026) & ($ million)
Table 20. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Patient (2021-2026)
Table 21. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Patient (2021-2026) & (US$/Ton)
Table 22. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale by Application (2021-2026) & (Tons)
Table 23. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Market Share by Application (2021-2026)
Table 24. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Application (2021-2026) & ($ million)
Table 25. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Application (2021-2026)
Table 26. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Application (2021-2026) & (US$/Ton)
Table 27. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Company (2021-2026) & (Tons)
Table 28. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Company (2021-2026)
Table 29. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Company (2021-2026) & ($ millions)
Table 30. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Company (2021-2026)
Table 31. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Price by Company (2021-2026) & (US$/Ton)
Table 32. Key Manufacturers Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Producing Area Distribution and Sales Area
Table 33. Players Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Products Offered
Table 34. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 35. New Products and Potential Entrants
Table 36. Market M&A Activity & Strategy
Table 37. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Geographic Region (2021-2026) & (Tons)
Table 38. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share Geographic Region (2021-2026)
Table 39. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 40. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Geographic Region (2021-2026)
Table 41. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country/Region (2021-2026) & (Tons)
Table 42. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country/Region (2021-2026)
Table 43. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country/Region (2021-2026) & ($ millions)
Table 44. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country/Region (2021-2026)
Table 45. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026) & (Tons)
Table 46. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country (2021-2026)
Table 47. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026) & ($ millions)
Table 48. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 49. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 50. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Region (2021-2026) & (Tons)
Table 51. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Region (2021-2026)
Table 52. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Region (2021-2026) & ($ millions)
Table 53. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 54. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 55. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026) & (Tons)
Table 56. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Country (2021-2026) & ($ millions)
Table 57. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 58. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 59. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Country (2021-2026) & (Tons)
Table 60. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country (2021-2026)
Table 61. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Type (2021-2026) & (Tons)
Table 62. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Application (2021-2026) & (Tons)
Table 63. Key Market Drivers & Growth Opportunities of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Table 64. Key Market Challenges & Risks of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Table 65. Key Industry Trends of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Table 66. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Raw Material
Table 67. Key Suppliers of Raw Materials
Table 68. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Distributors List
Table 69. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Customer List
Table 70. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Region (2027-2032) & (Tons)
Table 71. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 72. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Country (2027-2032) & (Tons)
Table 73. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 74. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Region (2027-2032) & (Tons)
Table 75. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Country (2027-2032) & (Tons)
Table 77. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Country (2027-2032) & (Tons)
Table 79. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Type (2027-2032) & (Tons)
Table 81. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 82. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Forecast by Application (2027-2032) & (Tons)
Table 83. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 84. AstraZeneca Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 85. AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 86. AstraZeneca Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 87. AstraZeneca Main Business
Table 88. AstraZeneca Latest Developments
Table 89. GlaxoSmithKline?GSK? Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 90. GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 91. GlaxoSmithKline?GSK? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 92. GlaxoSmithKline?GSK? Main Business
Table 93. GlaxoSmithKline?GSK? Latest Developments
Table 94. Pfizer Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 96. Pfizer Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. Bristol Myers Squibb?BMS? Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 100. Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 101. Bristol Myers Squibb?BMS? Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 102. Bristol Myers Squibb?BMS? Main Business
Table 103. Bristol Myers Squibb?BMS? Latest Developments
Table 104. Jiangsu Hengrui Pharmaceuticals Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 105. Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 106. Jiangsu Hengrui Pharmaceuticals Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 107. Jiangsu Hengrui Pharmaceuticals Main Business
Table 108. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 109. BeiGene Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 110. BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 111. BeiGene Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 112. BeiGene Main Business
Table 113. BeiGene Latest Developments
Table 114. Johnson & Johnson Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 115. Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 116. Johnson & Johnson Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 117. Johnson & Johnson Main Business
Table 118. Johnson & Johnson Latest Developments
Table 119. Merck & Co. Basic Information, Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Manufacturing Base, Sales Area and Its Competitors
Table 120. Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Product Portfolios and Specifications
Table 121. Merck & Co. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales (Tons), Revenue ($ Million), Price (US$/Ton) and Gross Margin (2021-2026)
Table 122. Merck & Co. Main Business
Table 123. Merck & Co. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Figure 2. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country/Region (2025)
Figure 10. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Olaparib
Figure 12. Product Picture of Niraparib
Figure 13. Product Picture of Talazoparib
Figure 14. Product Picture of Rucaparib
Figure 15. Product Picture of Fluzoparib
Figure 16. Product Picture of Pamiparib
Figure 17. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type in 2026
Figure 18. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Type (2021-2026)
Figure 19. Product Picture of BRCA-mutated
Figure 20. Product Picture of HRD-positive Broader Population
Figure 21. Product Picture of All-comers
Figure 22. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Patient in 2026
Figure 23. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Patient (2021-2026)
Figure 24. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Ovarian Cancer
Figure 25. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Ovarian Cancer (2021-2026) & (Tons)
Figure 26. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Breast Cancer
Figure 27. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Breast Cancer (2021-2026) & (Tons)
Figure 28. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Prostate Cancer
Figure 29. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Prostate Cancer (2021-2026) & (Tons)
Figure 30. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Pancreatic Cancer
Figure 31. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Pancreatic Cancer (2021-2026) & (Tons)
Figure 32. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Other HRD tumors
Figure 33. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Other HRD tumors (2021-2026) & (Tons)
Figure 34. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Market Share by Application (2025)
Figure 35. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Application in 2025
Figure 36. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Company in 2025 (Tons)
Figure 37. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Company in 2025
Figure 38. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Company in 2025 ($ millions)
Figure 39. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Company in 2025
Figure 40. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 43. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 44. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 45. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 46. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 47. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 49. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 50. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country in 2025
Figure 51. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country (2021-2026)
Figure 52. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 53. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 54. United States Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Region in 2025
Figure 59. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Region (2021-2026)
Figure 60. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 61. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 62. China Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 66. India Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country in 2025
Figure 70. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country (2021-2026)
Figure 71. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 72. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 73. Germany Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 74. France Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 81. Egypt Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) in 2026
Figure 87. Manufacturing Process Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Figure 88. Industry Chain Structure of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Figure 89. Channels of Distribution
Figure 90. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Forecast by Region (2027-2032)
Figure 91. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Figure 2. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Growth Rate 2021-2032 (Tons)
Figure 7. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country/Region (2025)
Figure 10. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Olaparib
Figure 12. Product Picture of Niraparib
Figure 13. Product Picture of Talazoparib
Figure 14. Product Picture of Rucaparib
Figure 15. Product Picture of Fluzoparib
Figure 16. Product Picture of Pamiparib
Figure 17. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type in 2026
Figure 18. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Type (2021-2026)
Figure 19. Product Picture of BRCA-mutated
Figure 20. Product Picture of HRD-positive Broader Population
Figure 21. Product Picture of All-comers
Figure 22. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Patient in 2026
Figure 23. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Patient (2021-2026)
Figure 24. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Ovarian Cancer
Figure 25. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Ovarian Cancer (2021-2026) & (Tons)
Figure 26. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Breast Cancer
Figure 27. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Breast Cancer (2021-2026) & (Tons)
Figure 28. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Prostate Cancer
Figure 29. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Prostate Cancer (2021-2026) & (Tons)
Figure 30. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Pancreatic Cancer
Figure 31. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Pancreatic Cancer (2021-2026) & (Tons)
Figure 32. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Consumed in Other HRD tumors
Figure 33. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Market: Other HRD tumors (2021-2026) & (Tons)
Figure 34. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sale Market Share by Application (2025)
Figure 35. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Application in 2025
Figure 36. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales by Company in 2025 (Tons)
Figure 37. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Company in 2025
Figure 38. Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue by Company in 2025 ($ millions)
Figure 39. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Company in 2025
Figure 40. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Geographic Region (2021-2026)
Figure 41. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Geographic Region in 2025
Figure 42. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 43. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 44. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 45. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 46. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 47. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 48. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales 2021-2026 (Tons)
Figure 49. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue 2021-2026 ($ millions)
Figure 50. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country in 2025
Figure 51. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country (2021-2026)
Figure 52. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 53. Americas Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 54. United States Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 55. Canada Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 56. Mexico Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 57. Brazil Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 58. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Region in 2025
Figure 59. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Region (2021-2026)
Figure 60. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 61. APAC Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 62. China Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 63. Japan Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 64. South Korea Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 65. Southeast Asia Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 66. India Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 67. Australia Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 68. China Taiwan Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 69. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country in 2025
Figure 70. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share by Country (2021-2026)
Figure 71. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 72. Europe Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 73. Germany Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 74. France Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 75. UK Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 76. Italy Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 77. Russia Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 78. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Country (2021-2026)
Figure 79. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Type (2021-2026)
Figure 80. Middle East & Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share by Application (2021-2026)
Figure 81. Egypt Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 82. South Africa Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 83. Israel Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 84. Turkey Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 85. GCC Countries Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Growth 2021-2026 ($ millions)
Figure 86. Manufacturing Cost Structure Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) in 2026
Figure 87. Manufacturing Process Analysis of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Figure 88. Industry Chain Structure of Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors)
Figure 89. Channels of Distribution
Figure 90. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Forecast by Region (2027-2032)
Figure 91. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share Forecast by Region (2027-2032)
Figure 92. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share Forecast by Type (2027-2032)
Figure 93. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share Forecast by Type (2027-2032)
Figure 94. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Sales Market Share Forecast by Application (2027-2032)
Figure 95. Global Poly ADP-ribose Polymerase Inhibitors(PARP Inhibitors) Revenue Market Share Forecast by Application (2027-2032)
